<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513303</url>
  </required_header>
  <id_info>
    <org_study_id>VT-304</org_study_id>
    <nct_id>NCT02513303</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety outcomes following use of the
      Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV
      fistula for vascular access (index procedure). Following successful creation of the AV
      fistula, the cohort randomized to the treatment group will receive the SeCI; the control
      group will not receive an implant. The primary hypothesis is that the proportion of subjects
      that meet requirements for fistula suitability for dialysis six months following the index
      procedure will be higher in the treatment group in comparison to the control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fistula Suitability for Dialysis at 6 Months (FSD6)</measure>
    <time_frame>6 months</time_frame>
    <description>For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation.
For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Complication of Renal Dialysis</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>End Stage Kidney Disease</condition>
  <condition>ESRD</condition>
  <condition>Chronic Kidney Failure</condition>
  <condition>Complication of Hemodialysis</condition>
  <condition>Vascular Access Complication</condition>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AV fistula surgery with investigational product (Sirolimus-eluting Collagen Implant)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>AV fistula surgery without investigational product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Subjects in the treatment group will receive a single prophylactic dose of sirolimus delivered locally to the vessel wall at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery. Control group subjects will have surgery for creation of the AV fistula but will not receive the drug.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently on hemodialysis for ≤12 months or expected to initiate hemodialysis within
             approximately 6 months of the creation of the AV fistula.

          -  Vascular anatomy suitable for creation of the AV fistula, determined by pre procedure
             duplex ultrasound

          -  Successful creation of a single stage radiocephalic or brachiocephalic end to side
             fistula

        Exclusion Criteria:

          -  Prior AV access created on the limb where the fistula surgery is planned

          -  ST-elevation MI or cerebrovascular accident within 30 days of the index procedure

          -  Known hypersensitivity to the following: sirolimus, beef or bovine collagen

          -  Hypotension with systolic blood pressures &lt;100 mm Hg at the time of screening

          -  Known or suspected active infection at the time of the AV fistula surgery

          -  Known to be HIV positive

          -  Prisoner, mentally incompetent, and/or alcohol or drug abuser
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Iyer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vascular Therapies, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh Raghubanshi</last_name>
    <phone>201-266-8310</phone>
    <email>rakesh@vasculartx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Kornhauser, EdD</last_name>
    <phone>954-341-1440</phone>
    <email>david@vasculartx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nephrology Consultants, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Service</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Diego Institute of Medical Research</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Raghubanshi</last_name>
      <phone>201-266-8310</phone>
      <email>rakesh@vasculartx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>End Stage Kidney Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Chronic Kidney Failure</keyword>
  <keyword>Chronic Renal Failure</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Access</keyword>
  <keyword>Arteriovenous Fistula</keyword>
  <keyword>AV Fistula</keyword>
  <keyword>AVF</keyword>
  <keyword>Nephrology</keyword>
  <keyword>Vascular Surgery</keyword>
  <keyword>Dialysis Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

